Liver Health Image

Liver health and dietary sugars

This content has been reviewed by Prof Leanne Hodson, Radcliffe Department of Medicine, University of Oxford, UK.

Liver health

The liver is the largest solid internal organ in the human body and has a major role in the digestion and processing of the foods we eat. Liver disease is a condition that affects the organ’s ability to process the products of digestion, rid the body of waste and keep the blood flowing well. 

There are many different types of liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) represents several different stages of liver disease and is caused by having too much fat in the liver. 

  • Metabolic means connected with how your body uses and stores energy from food. 
  • Dysfunction means that something isn’t working properly.
  • Associated means linked to.
  • Steatotic means fatty.
Liver health image
GP appointment image
MASLD excludes liver disease caused by excessive alcohol consumption, autoimmune diseases or viral infections. The initial stage of MASLD is the build-up of fat within the liver, followed by inflammation, damage to the liver tissues and scarring of the liver. The more serious stages include liver cancer and liver failure. The disease usually progresses through these different stages over many years. However, having one stage does not mean an individual will definitely develop the next one. There are many possible factors that affect the progression of MASLD, including genetic and lifestyle factors. There are often no specific symptoms, especially during the earlier stages. MASLD might only be diagnosed when it has become serious, or after having tests for other health problems. The further along the stages the condition progresses, the less reversible it is.

Risk factors for MASLD

Here are a few examples of MASLD risk factors:

Gender Males are more susceptible
Ethnicity Higher prevalence in Hispanic and Asian populations
Genetics Certain genes increase the risk 
Body fat High body fat and the distribution of fat in the body (having central or abdominal fat) are strong risk factors (3-5)

Liver disease and the diet

A healthy, balanced diet and lifestyle is important for maintaining a healthy weight and for staying fit and well. If a person exceeds their individual calorie (energy) requirements (i.e., they gain weight), this can increase liver fat content and increase their risk of MASLD (6). Most research looking at excess calories and risk of liver disease has focused on dietary fats and sugars.

Evidence suggests that exceeding calorie requirements, by consuming excess dietary fats or sugars from sugars-sweetened beverages, may increase the risk of MASLD (6). When dietary sugars are consumed as part of a diet where calorie intake is matched to calorie requirements (i.e., calorie neutral/body weight neutral), the effect on liver fat content is less clear, with most studies reporting no significant effect (7).   

Fructose and the liver

The effect of fructose-containing sugars on markers of MASLD appears mediated [driven] by both energy control and food source (7)

Fructose, as an added (or free) sugar in the diet, may play a unique role in the development and progression of MASLD, due to the difference in the way it is metabolised in the liver, compared to glucose. However, studies looking at this often use high doses of fructose, with a background diet exceeding a person’s calorie requirements. It is unclear if there is an increased risk of MASLD when consuming fructose-containing foods and drinks as part of a typical calorie-neutral diet. A recent review of the evidence, conducted by researchers at the University of Toronto, concluded that food source (i.e. the type of food), and calorie control, are important factors which influence the effect of fructose-containing sugars on the risk of MASLD (7).  The review found that:

  • In dietary interventions, when sugars-sweetened beverages (a source of fructose) were consumed at high doses and providing excess calories, there was an increase in liver fat and liver enzymes. Other fructose-containing food sources did not have a significant effect when consumed as extra calories (7). 
  • When fructose-containing foods and beverages were substituted for other sources of carbohydrates (glucose, sucrose, or starch), with no change in total calories in the diet, there was no independent effect of fructose. This suggests that the effect of fructose is not different from other carbohydrates in the diet (7).
  • Further longer-term research is required, using doses of fructose-containing foods and beverages typically found in the diet, consumed at different levels of calorie control (excess and neutral).
Man tracking diet

Prevention and treatment

To prevent liver disease progression to the more serious conditions of liver fibrosis and cirrhosis, early identification and effective management of MASLD are crucial. There are currently no approved medications to treat MASLD, although research into emerging treatments is currently underway. The primary treatment and preventative recommendations for MASLD are body weight reduction (if individuals have overweight or obesity), healthy dietary habits and increased physical activity. These measures can slow or even reverse MASLD, especially if it is at an earlier stage (8,9).

References

  1. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851–61. 
  2. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793–801. 
  3. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014 May 27;6(5):274–83. 
  4. Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity. J Clin Diagn Res. 2014 Jan;8(1):62–6. 
  5. Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015 Aug;35(3):270–90. 
  6. Tsompanaki E, Thanapirom K, Papatheodoridi M, Parikh P, Lima YC de, Tsochatzis EA. Systematic Review and Meta-analysis: The Role of Diet in the Development of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2023 Jun 1;21(6):1462-1474.e24. 
  7. Lee D, Chiavaroli L, Ayoub-Charette S, Khan TA, Zurbau A, Au-Yeung F, et al. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Nutrients. 2022 Jul 12;14(14):2846. 
  8. Beygi M, Ahi S, Zolghadri S, Stanek A. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions. Nutrients. 2024 Jul 11;16(14):2220. 
  9. Elshaer A, Chascsa DMH, Lizaola-Mayo BC. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Life (Basel). 2024 Jul 3;14(7):844.